- Quarterly Reports use Market Intelligence and Competitive Analysis from Thomson Reuters to Explore Various Aspects of the Pharmaceutical Pipeline
—
LONDON and PHILADELPHIA, August 18LONDON and PHILADELPHIA, August 18 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has announced the availability of the Pharma Matters reports covering the time period January-March 2008. Launched more than two years ago, the quarterly Pharma Matters reports cover all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon Premium(TM) and the Thomson Messaging Mapping System(SM).
The Ones to Watch -- A Thomson Reuters quarterly review of the latest phase changes in the pharmaceutical pipeline, this report is based on the strategic data and analysis from Thomson Pharma, the world's leading pharmaceutical competitive intelligence solution. In the report covering Q1 2008, the top five most promising drugs launched or receiving approval were:
DRUG DISEASE COMPANY Intelence(TM) HIV-1 infection Tibotec Pristiq(TM) Depression Wyeth Ionsys(TM) Acute pain ALZA Arcalyst(TM) CIAS1-associated Regeneron periodic syndromes Moxatag(TM) Streptococcus MiddleBrook pyogenes-associated pharyngitis, tonsillitis
More analysis, as well as information on drugs entering clinical Phases I, II and III, are available in the full report: http://scientific.thomsonreuters.com/thomsonpharma/media/pdfs/tpqr/totw_jan-m arch_08.pdf (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)
Movers and Shakers -- Introduced in mid-2007, this report is the newest in the Pharma Matters series and covers the U.S. generics industry using data and analysis from Newport Horizon Premium, the critical product targeting the global business development system. Analysis from the Q1 2008 report includes:
-- The U.S. generics market is remarkably robust but will be hit by the current downturn in drugs innovation, which will translate into a decline in off-patent drugs from 2012. -- 'Super Generic' companies such as Teva and Mylan now dominate the generics market and will be the best placed to survive any future downturns. -- During the first quarter of 2008, final approvals were issued on 134 'A'-rated ANDAs, up from 108 the quarter before. -- 11 new products (four combination products and seven single active ingredient products) were subjected to paragraph IV challenges for the first time in Q1 2008, in comparison to the challenges made to seven new products in the last quarter of 2007. -- During the first quarter of 2008, the largest number of ANDA approvals went to US-based companies. Thirty different US-based corporations received a total of 59 final ANDA approvals. -- In the same time period, fourteen India-based companies received a total of 36 approvals, putting India in second place.
To learn more about companies making their mark on the U.S. generics market, click on this link to read the full report: http://scientific.thomson.com/thomsonpharma/media/pdfs/tpqr/movers_shakers_ja n-mar08.pdf (Due to the length, copy and paste URL into browser window.)
Who is Making the Biggest Splash? -- This report is a Thomson Reuters expert review of the organizations that are helping to shape professional opinions on drugs and therapies, using the unique insights of the Thomson Message Mapping System. In this quarterly review of the scientific literature on drugs and therapies, Thomson Reuters assesses the quantity and quality of the materials published by pharmaceutical companies, research institutions and other non-commercial bodies. The top five of the listed 15 organizations that have made the biggest impact as the leading sources of information on medical research from January-March 2008 are:
1. Eli Lilly 2. sanofi-aventis 3. Novartis 4. Bristol-Myers Squibb 5. GlaxoSmithKline
To see the complete list, as well as analysis and methodology, click to read the full report: http://scientific.thomsonreuters.com/thomsonpharma/media/pdfs/tpqr/making -a-splash-mar2008.pdf (Due to the length, copy and paste URL into browser window.)
To sign up for the Thomson Reuters Pharma Matters series of publications visit: scientific.thomson.com/pharma/forms/matters/
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.
Web site: http://www.thomsonreuters.com http://scientific.thomson.com/pharma/forms/matters
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
